Intelligent Bio Solutions Enhances FDA Submission with Key Data
Intelligent Bio Solutions Inc. (NASDAQ: INBS), a prominent medical technology company renowned for its innovative, non-invasive testing solutions, has taken substantial strides in its application process for FDA 510(k) clearance. Recently, the company warmly announced the submission of its Additional Information (AI) response to the FDA, which bolsters its ongoing efforts for market entry in the United States, expected to occur later this year.
Strengthening the 510(k) Submission
The recent updates in the submission involve new promising data that not only strengthens the company's 510(k) filing, but also reinforces the security and performance metrics of its cutting-edge fingerprint sweat-based drug screening technology. This breakthrough approach aims to enhance drug testing protocols efficiently and reliably.
Robust Cybersecurity Testing
To support the updated filing, Intelligent Bio Solutions has incorporated results from extensive cybersecurity assessments, including rigorous penetration testing and evaluations for electromagnetic compatibility. The dedication to these measures has established the technology's resilience across diverse environments, underscoring targeted improvements to the system's integrity and reliability. To achieve this, the company invested an impressive 10,000 hours in data collection for the submission, generating an extensive documentation package consisting of 23 detailed test reports and over 1,900 pages of supporting materials.
Reliable Technology Validation
Peter Passaris, Vice President of Product Development at Intelligent Bio Solutions, expressed enthusiasm regarding this development. He emphasized, "The quality, depth, and regulatory compliance demonstrated in our submission mark significant progress. Our dedicated team has displayed remarkable dedication during the information review period, and we are excited about the robustness of the package we’re presenting."
Commitment to Accuracy through Advanced Techniques
Intelligent Bio Solutions proudly reaffirms the precision of its technology using sophisticated quantification methods, including analysis of human eccrine sweat samples. An Ultra-Micro Balance scale, noted for its sensitivity, validated the system's capability to detect and assess tiny volumes of sweat present in a mere fingerprint. This innovation could fundamentally change workplace drug testing practices.
Focus on U.S. Market Launch
Harry Simeonidis, the President and CEO of Intelligent Bio Solutions, emphasized that gaining FDA clearance is paramount for introducing their advanced fingerprint sweat-based solution to substantial markets, particularly the lucrative U.S. market. He stated, "The data we have compiled showcases the exemplary efforts of our R&D team, which has played a pivotal role in enhancing the accuracy and dependability of our technology."
Strategic Expansion Plans
As part of its strategic initiative, Intelligent Bio Solutions is committed to advancing its U.S. expansion strategy, with a focus on gaining FDA clearance for its opiate testing system for codeine, aiming for market entry in the near future. The company's non-invasive drug screening technology is already being utilized by more than 450 establishments across 24 nations, serving sectors such as law enforcement, workplace safety, and justice. With 18 global distribution partnerships and a rising awareness locally and globally, Intelligent Bio Solutions is increasingly solidifying its international footprint. Breaking into the billion-dollar U.S. marketplace presents immense opportunities for the company as it continues to aspire towards global growth and advancement.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology entity dedicated to delivering quick, reliable, non-invasive testing solutions. The firm is confident that its Intelligent Fingerprinting Drug Screening System can transform portable drug testing via fingerprint sweat analysis, potentially extending its realms of application beyond current markets. The system is distinctively designed to be hygienic and cost-efficient, capable of screening for recent drug use in various workplaces, such as opiates, cocaine, methamphetamine, and cannabis. Notably, it enables swift sample collection and produces outcomes in under ten minutes, making it a vital resource for employers in critical safety environments.
Frequently Asked Questions
What advancements has Intelligent Bio Solutions made in its FDA submission?
The company has submitted additional data including cybersecurity and performance metrics to strengthen its FDA 510(k) filing.
What type of drug testing technology is Intelligent Bio Solutions developing?
They are developing a fingerprint sweat-based drug screening technology intended for rapid and non-invasive testing environments.
What is the significance of the FDA clearance for the company?
FDA clearance is crucial for Intelligent Bio Solutions as it aims to introduce its innovative drug testing technology into the lucrative U.S. market.
How does their testing technology work?
The technology utilizes fingerprint sweat analysis to screen for drugs, providing quick results and requiring minimal sample collection time.
What markets is Intelligent Bio Solutions targeting with its technology?
The company aims to serve various sectors including workplaces, law enforcement, and justice systems, with expansion plans targeting the U.S. market.
